Form 8-K
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2011

Athersys, Inc.
(Exact name of registrant as specified in its charter)

         
Delaware   001-33876   20-4864095
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
3201 Carnegie Avenue, Cleveland, Ohio
   44115-2634
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (216) 431-9900

 
 
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 14, 2011, the Board of Directors of Athersys, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board of Directors of the Company, approved the following cash bonuses to the named executive officers of the Company, based on Company performance in 2010:
             
Name   Title   Award
Dr. Gil Van Bokkelen  
Chief Executive Officer
  $ 52,750  
 
William Lehmann, Jr.  
President and Chief Operating Officer
  $ 45,214  
 
Dr. John Harrington  
Chief Scientific Officer and Executive Vice President
  $ 45,214  
 
Dr. Robert Deans  
Senior Vice President — Regenerative Medicine
  $ 35,418  
 
Laura Campbell  
Vice President of Finance
  $ 29,389  

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2011

ATHERSYS, INC.

By: /s/ Laura K. Campbell                            
Name: Laura K. Campbell
Title: Vice President of Finance

 

3